NCT05525715: A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 1/2 | 260 | NA | 2mg QY201 tablets or 2mg QY201 placebo,BID, 5mg QY201 tablets or 5mg QY201 placebo,BID, 10mg QY201 tablets or 10mg QY201 placebo,QD, 10mg QY201 tablets or 10mg QY201 placebo,BID, 15mg QY201 tablets or 15mg QY201 placebo,BID, 20mg QY201 tablets or 20mg QY201 placebo,BID, 5mg QY201 tablets，BID, 10mg QY201 tablets，BID, 20mg QY201 tablets，BID, QY201 placebo，BID | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Atopic Dermatitis | 12/25 | 12/25 | | |
ChiCTR2100053527: A randomized, double-blind, dose-escalation study of tolerability, pharmacokinetics and food effects of single and multiple oral administration of QY201 tablets in healthy Chinese subjects |
|
|
| Completed | 1 | 136 | | single dose escalation ;multiple dose escalation ;take QY201 tablets orally on an empty stomach or after eating a high-fat and high-calorie standard meal in the morning of Day 1 and Day 6 | The Second Affiliated Hospital Zhejiang University School of Medicine; E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., self-funded | Atopic dermatitis | | | | |
